SynapDx Corporation, Broad Institute Collaborate on NGS Analytics for Diagnostic Applications
News Mar 17, 2014
SynapDx Corporation today announced that it has formed a collaboration with the Broad Institute of Harvard and MIT. The collaboration brings together scientists with leading expertise in computational biology and software engineering to accelerate advances in next generation sequencing.
SynapDx is currently conducting one of the largest prospective, multi-center studies to analyze blood from children undergoing clinical evaluation for autism spectrum disorder (ASD). The objective of the collaboration is to develop advanced next generation sequencing (NGS) analysis techniques to further enhance test accuracy and clinical utility in autism diagnostics.
"We are thrilled to be working with SynapDx. Our collaboration will enable us to really push the methods for variant detection in new directions," said Eric Banks, Group Leader of Genome Sequencing and Analysis at the Broad Institute.
“Our partnership with the Broad Institute helps advance our mission by developing powerful tools for the analysis of next generation sequencing data that will have broad application in the detection of autism and beyond ,” said Mark DePristo, SynapDx Vice President of Informatics .
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE